Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 26:e254813.
doi: 10.1001/jamaophthalmol.2025.4813. Online ahead of print.

Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome

Nancy Aychoua  1   2 , Thales A C de Guimarães  1   2 , Manav B Ponnekanti  3 , Sajin Sasidharan  2 , Sum-Ping Leung  3 , Folahan Adesola Ibukun  4 , Naomi James  1   2 , Vanita Berry  1 , Omar A Mahroo  1   2 , Andrew R Webster  1   2 , Angelos Kalitzeos  1   2 , Michel Michaelides  1   2
Affiliations

Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome

Nancy Aychoua et al. JAMA Ophthalmol. .

Abstract

Importance: Expanding insight into the phenotypic spectrum, social burden of dual sensory impairment, and progression of USH1C-associated retinopathy is essential to inform prognosis and guide emerging therapies.

Objective: To characterize some genetic variants, clinical features, natural history, and social outcomes of USH1C-associated retinopathy in a patient cohort.

Design, setting, and participants: This was a retrospective case series including patients with molecularly confirmed UCH1C-associated retinopathy evaluated at a tertiary referral center from January 1989 to February 2024.

Exposure: Molecularly confirmed pathogenic variants in USH1C.

Main outcomes and measures: Main outcomes included best-corrected visual acuity (BCVA) measured with the Snellen chart, retinal imaging features, genetic variants, and patient-reported social outcomes. Depression was documented by general practitioners using the Patient Health Questionnaire 9. Unemployment was self-reported at last follow-up. Retinitis pigmentosa diagnosis (RP) was diagnosed based on characteristic retinal findings and visual field loss.

Results: A total of 28 patients (mean [SD] age, 27.0 [12.2] years; range, 7-58 years; 15 female [53.6%]) were included in this analysis. Two novel pathogenic USH1C variants were identified; 18 patients were homozygous. Presenting symptoms included nyctalopia (24 of 26 patients [92.3%]) and peripheral vision difficulties (23 of 28 patients [82.1%]). Baseline BCVA (Snellen chart) in the better-seeing eye (n = 25) was 0.22 logMAR (20/32). Among 15 patients with follow-up of 5 years or more, baseline BCVA was 0.30 logMAR (20/40), declining to 0.59 logMAR (20/80). In Early Treatment Diabetic Retinopathy Study (ETDRS) equivalents (n = 15), decline averaged 0.53 letters per year (median, 0; range, 0-2). Four of 24 patients (16.7%) met World Health Organization criteria for severe sight impairment (20/200 or worse in the better-seeing eye). Depression was reported by 5 of 13 patients (38.5%) and unemployment by 7 of 23 patients (30.4%). Optical coherence tomography revealed cystoid macular edema in 5 of 21 patients at baseline, persisting in 2 patients at follow-up. Mean (SD) central subfield thickness was 260.6 (53.6) µm at baseline (n = 18) and 259.4 (44.5) µm at follow-up (n = 15). Patients with missense variants c.308G>A (p.Arg103His) and c.440A>G (p.His147Arg) showed retinitis pigmentosa sparing the superior retina.

Conclusions and relevance: Results of this case series study suggest that USH1C-associated retinopathy was characterized by slow decline of visual acuity and modest ellipsoid zone loss over decades. Depression and unemployment were also observed, with implications for prognosis and counseling. Early onset and slow progression highlight its potential as a target for emerging therapies.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr de Guimarães reported receiving a fellowship award from Foundation Fighting Blindness outside the submitted work. Dr Mahroo reported receiving advisory board fees from Janssen Pharmaceuticals and grants from Wellcome Trust and the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology outside the submitted work. Dr Kalitzeos reported receiving grants from NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and the National Eye Institute, National Institutes of Health outside the submitted work. Dr Michaelides reported receiving consultant fees from MeiraGTx, Janssen Pharmaceuticals, Saliogen, and AAVantgarde and grants from NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, Moorfields Eye Charity, and the Wellcome Trust outside the submitted work. No other disclosures were reported.

References

    1. Ko AS, Pfeifer WL, Drack AV. Is it Usher syndrome—diagnosing children with hearing loss and ocular findings. J AAPOS. 2015;19(4):e50. doi: 10.1016/j.jaapos.2015.07.155 - DOI
    1. Guimaraes TAC, Arram E, Shakarchi AF, Georgiou M, Michaelides M. Inherited causes of combined vision and hearing loss: clinical features and molecular genetics. Br J Ophthalmol. 2023;107(10):1403-1414. doi: 10.1136/bjo-2022-321790 - DOI - PubMed
    1. Delmaghani S, El-Amraoui A. The genetic and phenotypic landscapes of Usher syndrome: from disease mechanisms to a new classification. Hum Genet. 2022;141(3-4):709-735. doi: 10.1007/s00439-022-02448-7 - DOI - PMC - PubMed
    1. Bauwens M, De Man V, Audo I, et al. Expanding the genetic landscape of Usher syndrome type IV caused by pathogenic ARSG variants. Clin Genet. 2025;107(1):44-55. doi: 10.1111/cge.14614 - DOI - PMC - PubMed
    1. Koenekoop RK, Arriaga M, Trzupek KM, eds, et al. Usher syndrome type I. In: GeneReviews [Internet]. University of Washington; 1993. - PubMed

LinkOut - more resources